Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.2% - Here's What Happened

Key Points

• Shares rose 6.2% to $27.41 mid-day on Friday with ~1.12 million shares traded (about 5% below average); the stock has a $1.26 billion market cap and a 50-day/200-day moving average of $25.41/$15.51, reflecting recent strength.
• Analysts sharply raised targets — Oppenheimer to $54, Piper Sandler to $45 and HC Wainwright to $60 — leaving consensus at nine Buys and one Sell with an average price target of $40.82.
• Company focus: Capricor is a clinical-stage biotech developing cell- and exosome-based therapies (lead candidate CAP-1002) for conditions including Duchenne muscular dystrophy and COVID-19-related heart injury.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report)'s stock price was up 6.2% during mid-day trading on Friday . The company traded as high as $27.41 and last traded at $27.41. Approximately 1,121,213 shares changed hands during trading, a decline of 5% from the average daily volume of 1,184,921 shares. The stock had previously closed at $25.82.

Analyst Ratings Changes

Several equities research analysts recently commented on CAPR shares. Oppenheimer boosted their price target on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the stock an "outperform" rating in a report on Monday, December 8th. Piper Sandler reissued an "overweight" rating and set a $45.00 target price (up from $20.00) on shares of Capricor Therapeutics in a research note on Wednesday, December 10th. HC Wainwright upped their price target on shares of Capricor Therapeutics from $24.00 to $60.00 and gave the stock a "buy" rating in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a "sell (e+)" rating on shares of Capricor Therapeutics in a report on Monday, December 29th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Capricor Therapeutics in a research note on Wednesday, January 14th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Capricor Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $40.82.

Capricor Therapeutics Price Performance

The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -15.27 and a beta of 0.37. The firm has a fifty day moving average of $25.41 and a 200 day moving average of $15.51.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Farther Finance Advisors LLC purchased a new stake in shares of Capricor Therapeutics during the third quarter worth $28,000. Parkside Financial Bank & Trust purchased a new stake in Capricor Therapeutics during the 3rd quarter worth about $36,000. Russell Investments Group Ltd. increased its holdings in Capricor Therapeutics by 122.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company's stock worth $37,000 after purchasing an additional 2,786 shares during the period. ACT Capital Management LLC acquired a new stake in Capricor Therapeutics in the 4th quarter valued at about $43,000. Finally, GoalVest Advisory LLC purchased a new position in shares of Capricor Therapeutics in the 4th quarter valued at about $59,000. Hedge funds and other institutional investors own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.